BlackRock Inc. reduced its holdings in shares of Balchem Co. (NASDAQ:BCPC) by 0.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,664,616 shares of the basic materials company’s stock after selling 33,364 shares during the quarter. BlackRock Inc. owned approximately 14.43% of Balchem worth $432,877,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also bought and sold shares of BCPC. Norges Bank acquired a new stake in shares of Balchem in the fourth quarter worth approximately $33,642,000. Vanguard Group Inc raised its stake in shares of Balchem by 2.6% during the third quarter. Vanguard Group Inc now owns 3,252,944 shares of the basic materials company’s stock valued at $364,622,000 after purchasing an additional 81,119 shares during the period. Wasatch Advisors Inc. raised its stake in shares of Balchem by 6.3% during the first quarter. Wasatch Advisors Inc. now owns 1,232,837 shares of the basic materials company’s stock valued at $114,407,000 after purchasing an additional 73,439 shares during the period. Ellis Investment Partners LLC purchased a new stake in shares of Balchem during the first quarter valued at approximately $49,000. Finally, 361 Capital LLC purchased a new stake in shares of Balchem during the first quarter valued at approximately $2,965,000. Hedge funds and other institutional investors own 87.00% of the company’s stock.
BCPC has been the topic of a number of analyst reports. Pivotal Research lowered shares of Balchem from a “buy” rating to a “hold” rating and set a $100.00 price objective on the stock. in a research note on Monday, May 6th. Zacks Investment Research lowered shares of Balchem from a “buy” rating to a “hold” rating in a research note on Wednesday, May 8th. BidaskClub lowered shares of Balchem from a “buy” rating to a “hold” rating in a research note on Thursday, May 23rd. Finally, HC Wainwright restated a “buy” rating and issued a $110.00 price target on shares of Balchem in a research note on Monday, May 6th. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $112.50.
Balchem (NASDAQ:BCPC) last announced its quarterly earnings results on Friday, May 3rd. The basic materials company reported $0.73 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.69 by $0.04. The business had revenue of $157.00 million during the quarter, compared to analysts’ expectations of $165.57 million. Balchem had a return on equity of 14.11% and a net margin of 12.20%. The firm’s quarterly revenue was down 2.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.76 EPS. Equities research analysts anticipate that Balchem Co. will post 2.97 earnings per share for the current fiscal year.
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization, and industrial markets in the United States and internationally. The company's Human Nutrition & Health segment supplies ingredients in the food and beverage industry.
Featured Article: What is a management fee?
Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.